Spark Newswire Spark Newswire
  • Newswire
  • News
    • Guidance
    • Dividends
    • M&A
    • Buybacks
    • Legal
    • Interviews
    • Management
    • Offerings
    • IPOs
    • Insider Trades
    • Biotech/FDA
    • Tech
  • Markets
    • After Hours
    • Movers
    • ETFs
    • Forex
    • Commodities
    • Options
    • Binary Options
    • Bonds
    • Futures
    • Global Economics
    • Reviews
    • Small-Cap
    • Cryptocurrency
    • Penny Stocks
  • Analysts
    • Analyst Color
    • Analyst Ratings
    • Upgrades
    • Downgrades
  • Earnings
    • Earnings
  • Support & Feedback
  • Registration Options
  • Log In
News by Category
  • After-Hours Center
  • Analyst Color
  • Analyst Ratings
  • Asia
  • Asset Sales
  • Binary Options
  • Biotech
  • Bonds
  • Broad U.S. Equity ETFs
  • Buybacks
  • Cannabis
  • Commodities
  • Contracts
  • Crowdsourcing
  • Cryptocurrency
  • Currency ETFs
  • Dividends
  • Downgrades
  • Earnings
  • Earnings Beats
  • Earnings Misses
  • Econ #s
  • Economics
  • Education
  • Emerging Market ETFs
  • Emerging Markets
  • Entertainment
  • Entrepreneurship
  • Equities
  • ESG
  • ETFs
  • Eurozone
  • Events
  • Exclusives
  • FDA
  • Federal Reserve
  • Financial Advisors
  • Financing
  • Fintech
  • Forex
  • Futures
  • Gaming
  • General
  • Global
  • Government
  • Guidance
  • Health Care
  • Hedge Funds
  • Hot
  • Initiation
  • Insider Trades
  • Insurance
  • Interview
  • Intraday Update
  • IPOs
  • Large Cap
  • Latin America
  • Legal
  • Long Ideas
  • M&A
  • Macro Economic Events
  • Macro Notification
  • Management
  • Market Summary
  • Market-Moving Exclusives
  • Markets
  • Media
  • Mid Cap
  • Movers
  • Movers & Shakers
  • Mutual Funds
  • New ETFs
  • News
  • Offerings
  • Opinion
  • Options
  • Penny Stocks
  • Personal Finance
  • Politics
  • Pre-Market Outlook
  • Prediction Markets
  • Press Releases
  • Previews
  • Price Target
  • Psychedelics
  • Psychology
  • Real Estate
  • Regulations
  • REIT
  • Reiteration
  • Restaurants
  • Retail Sales
  • Reviews
  • Rumors
  • SEC
  • Sector ETFs
  • Short Ideas
  • Short Sellers
  • Signals
  • Small Business
  • Small Cap
  • Small Cap Analysis
  • Small-Cap
  • Social Media
  • SPACE
  • Specialty ETFs
  • Sports
  • Sports Betting
  • Startups
  • Stock Split
  • Success Stories
  • Tech
  • Technicals
  • Termination
  • Top Stories
  • Topics
  • Trading Ideas
  • Travel
  • Treasuries
  • Uncategorized
  • Upgrades
  • WIIM
Spark Newswire Spark Newswire
Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.
  • Newswire
  • News
    • Guidance
    • Dividends
    • M&A
    • Buybacks
    • Legal
    • Interviews
    • Management
    • Offerings
    • IPOs
    • Insider Trades
    • Biotech/FDA
    • Tech
  • Markets
    • After Hours
    • Movers
    • ETFs
    • Forex
    • Commodities
    • Options
    • Binary Options
    • Bonds
    • Futures
    • Global Economics
    • Reviews
    • Small-Cap
    • Cryptocurrency
    • Penny Stocks
  • Analysts
    • Analyst Color
    • Analyst Ratings
    • Upgrades
    • Downgrades
  • Earnings
    • Earnings
  • Support & Feedback
  • Registration Options
  • Log In
Spark Newswire Spark Newswire
Filter By Ticker
Search By Date To
Today | Yesterday | This week

Latest news

Group By Ticker
Sort By
Newest | Oldest
Read More
2 minute read
  • Biotech
  • FDA
  • General
  • IPOs
  • News
  • Top Stories

The Week Ahead In Biotech (Dec. 19-25): Amgen And Aquestive Regulatory Decisions Key Events Of Holiday-Shortened Week

By Shanthi Rexaline
Today, 10:25 PM
Biotech stocks reversed course and advanced solidly in the week ending Dec. 17, as an increase in risk aversion pushed investors to buy into defensive stocks. The sector also drew strength from some positive stock-specific news.

AMGN

Read More
2 minute read
  • Movers

12 Health Care Stocks Moving In Wednesday’s After-Market Session

By Benzinga Insights
Today, 10:25 PM
Gainers

ADTX

Read More
1 minute read
  • News

Aquestive Therapeutics Granted U.S. Patent #11,191,737 ‘Enhanced delivery epinephrine compositions’

By Charles Gross
Today, 10:25 PM
View Patent here

AQST

Read More
6 minute read
  • Biotech
  • FDA
  • General
  • News
  • Penny Stocks
  • Small Cap
  • Top Stories

Attention Biotech Investors: Mark Your Calendar For December PDUFA Dates

By Shanthi Rexaline
Today, 10:25 PM
A majority of verdicts handed down by the FDA in November were positive. Three new molecular entities were approved during the month, taking the total number of NME approvals for the year-to-date period to 45. This is just one short of NME approvals received for the same period last year.

ABBV

Read More
1 minute read
  • Earnings
  • News

Aquestive Therapeutics Q3 EPS $(0.37) Beats $(0.45) Estimate, Sales $13.29M Beat $11.01M Estimate

By Benzinga Newsdesk
Today, 10:25 PM
Aquestive Therapeutics (NASDAQ:AQST) reported quarterly losses of $(0.37) per share which beat the analyst consensus estimate of $(0.45) by 17.78 percent. This is a 24.49 percent increase over losses of $(0.49) per share

AQST

Read More
19 minute read
  • Earnings
  • Markets
  • News
  • Pre-Market Outlook

Earnings Scheduled For November 2, 2021

By Benzinga Insights
Today, 10:25 PM
  Companies Reporting Before The Bell • Thomson Reuters (NYSE:TRI) is expected to report quarterly earnings at $0.48 per share on revenue of $1.86 billion.

AC

Read More
1 minute read
  • Movers
  • News
  • Trading Ideas

Watching Shares Of Cybin, Aquestive Therapeutics; Traders Circulate TipRanks Report ‘2 “Strong Buy” Penny Stocks That Could Spike Over 200%’ Mentioning Stocks

By Benzinga Newsdesk
Today, 10:25 PM
https://www.tipranks.com/news/article/2-strong-buy-penny-stocks-that-could-spike-over-200

AQST

Read More
1 minute read
  • Contracts
  • News

IntelGenx And Aquestive Therapeutics Partner With Leading Men’s Health Company To Market Tadalafil Oral Films In The U.S.

By Benzinga Newsdesk
Today, 10:25 PM
IntelGenx Corp. (TSXV:IGX) (OTCQB:IGXT) (“IntelGenx”) today announced that its co-development and commercialization partner for Tadalafil oral films for the treatment of erectile dysfunction

AQST

Read More
2 minute read
  • Intraday Update
  • Markets
  • Movers

12 Health Care Stocks Moving In Monday’s Intraday Session

By Benzinga Insights
Today, 10:25 PM
 

ABSI

Read More
1 minute read
  • Earnings

Looking into Aquestive Therapeutics’s Return on Capital Employed

By Benzinga Insights
Today, 10:25 PM
After pulling data from Benzinga Pro it seems like during Q2, Aquestive Therapeutics's (NASDAQ:AQST) reported sales totaled $15.35 million. Despite a 23.55% in earnings, the company posted a loss of $6.52 million.

AQST

Posts navigation

Previous 1 … 5 6 7 8 Next
Free Newsletter subscribe

Stock Market Ideas & Analysis

Stay up-to-date with the same information professionals use.
Spark Newswire Spark Newswire
  • Newswire
  • Registration
  • Log In
  • Settings
  • Privacy Policy
  • Terms of Service
© 2021 Spark Newswire
All Rights Reserved.

All news is property of their respective owners. Terms of Service